CRISPR/Cas9 as a genome‐editing tool for gene therapy induces p53 activation due to DSB repair,[88, 89] which may be advantageous for treating cancers harboring p53 mutation, but otherwise reduces the Indel generation efficiency in cells. This evidence concerns the gene TP53 and cancer.